FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma

On August 16, 2018, the U.S. Food and Drug Administration approved lenvatinib (Lenvima, Eisai Inc.) for first‐line treatment of patients with unresectable hepatocellular carcinoma (HCC). Approval was based on an international, multicenter, randomized, open‐label, noninferiority trial (REFLECT; NCT01...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncologist
Main Authors: Nair, Abhilasha, Reece, Kelie, Donoghue, Martha B., Yuan, Weishi (Vivian), Rodriguez, Lisa, Keegan, Patricia, Pazdur, Richard
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2020
Teme:
Regulatory Issues: FDA
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930400/
https://ncbi.nlm.nih.gov/pubmed/33044793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13566
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki